GSK has bolstered its position in the oligonucleotide therapeutics space through a four-year collaboration with Wave Life Sciences valued at up to $3.3 billion.
In the partnership announced Tuesday, GSK will harness Wave’s PRISM technology, an oligonucleotide platform that combines novel chemistry with multiple therapeutic modalities, including editing, splicing and silencing.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,